Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 495 of 5804
-
New injectable drug aims to tame blood sugar in type 2 diabetes
Disease control CompletedThe primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 36 weeks of treatment
Phase: PHASE3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for Tough-to-Treat colorectal cancer: drug targets specific protein
Disease control OngoingColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab adizutecan in adult participants with c-Met protein a…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New study aims to end HIV in latinx men with One-Stop PrEP shops
Prevention Recruiting nowThis study aims to learn how to help enable healthy behaviors and lower the risk of HIV among Latinx Men.
Phase: NA • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
New hope for stomach cancer: adding surgery to drug therapy may improve outcomes
Disease control Recruiting nowROSETTE trial is an open-label, randomized phase II study designed to investigate treatment strategies for patients with limited metastatic gastric or gastroesophageal adenocarcinoma. Eligible patients are randomized to receive either systemic treatment followed by surgeon-led lo…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New vaccine aims to outsmart ovarian cancer recurrence
Disease control Recruiting nowThis phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopian tube or primary peritoneal cancer. FRαDCs, a dendritic cell vaccine, is made from a person's white blood cells. The wh…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug targets Hard-to-Treat cancer mutation in early trial
Disease control Recruiting nowThis is a first in human (FIH), Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of RNK08954 to determine the optimal dose and recommended dose for expansion and evaluate clinical activity in patients…
Phase: PHASE1, PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Two-Drug immune attack shows promise against returning brain tumors
Disease control TerminatedThis phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatl…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug aims to tame rare bleeding disorder
Disease control OngoingThe purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients …
Phase: PHASE1, PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New heart implant aims to cut stroke risk without blood thinners
Disease control OngoingThe primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Leukemia treatment break: study tests pausing chemo for AML patients
Disease control Recruiting nowThe purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increa…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New asthma shot could slash attacks for High-Risk patients
Disease control OngoingThis is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in ma…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug cocktail aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis study is a open, multi-center phase II clinical study to explore the efficacy, safety and pharmacokinetic/pharmacodynamic characteristics of SI-B001+SI-B003 combined with platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic head and ne…
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug cocktail aims to crush resistant leukemia
Disease control Recruiting nowThis phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine kinase inhibitors (BTKi). Pir…
Phase: PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Nanoengineered patches and injectables aim to fight cancer locally
Disease control Recruiting nowArm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Situ (CIS) (WHO 2017) Arm 2 (Phase 1) PRV2…
Phase: PHASE2, PHASE3 • Sponsor: Privo Technologies • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control TerminatedThis phase Ib trial tests the safety, side effects, and effectiveness of humanized (hu)CD19-chimeric antigen receptor (CAR) T cell therapy in treating patients with CD19 positive B-cell acute lymphoblastic leukemia (ALL) that has come back after a period of improvement (relapsed)…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
At-Home breath test could help prevent stomach cancer
Prevention OngoingH. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive …
Phase: PHASE4 • Sponsor: University of Miami • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
One-Week brain zaps could Fast-Track PTSD recovery
Symptom relief Recruiting nowThis study will test the clinical efficacy of an accelerated TMS (accel-TMS) protocol that rapidly addresses PTSD symptoms with 1 week (25 sessions over 5 days) of condensed treatment.
Phase: NA • Sponsor: Florida State University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy shows promise for aggressive breast cancer in early trial
Disease control Recruiting nowWe plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo therapy shows promise for rare lung cancer
Disease control OngoingThis is a prospective, open-label, multi-site Phase II trial of pembrolizumab in combination with pemetrexed and cisplatin or carboplatin as neo-adjuvant therapy followed by surgery and adjuvant pembrolizumab in patients affected by resectable stage I-IIIa chemonaïve epithelioid/…
Phase: PHASE2 • Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New Parkinson's drug aims to smooth out 'Off' episodes
Disease control CompletedThe study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's D…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC